Return to program book search
Dermatologic Manifestations of New Oncology Drugs
Sunday, March 23
Mile High Ballroom 3B
1:00 PM - 3:00 PM
Mario E. Lacouture, MD, FAAD
- Milan J. Anadkat, MD, FAAD
- Jennifer N. Choi, MD, FAAD
- Nicole LeBoeuf, MD, FAAD
- Beth McLellan, MD, FAAD
Following this course, the attendee should be able to:
- Recognize clinical and histologic characteristics of dermatologic adverse events to new anticancer therapies.
- Describe the mechanisms involved in dermatologic adverse events to therapies in cancer.
- Discuss mechanistically-based interventions to improve quality of life and decrease dermatologic toxicities to anticancer therapies.
Systemic anticancer therapies (chemotherapy and targeted therapies), radiation, and surgeries have resulted in remarkable improvements in clinical outcomes in cancer, but the majority of patients will develop dermatologic adverse events, which lead to decreased quality of life and inconsistent antineoplastic therapy, both of which may affect survival. This session will provide a comprehensive understanding of dermatologic adverse events in cancer patients, so that dermatologists may play an integral role in the optimization of anticancer therapies and maintenance of quality of life.
|Sunday, March 23|
|1:00 PM||Introduction to Supportive Oncodermatology / Dr. Lacouture|
|1:10 PM||Skin Adverse Events Induced by Cyotoxic Chemotherapy (Alkylating, Antimetabolites, Topoisomerase inhibitors) / Dr. Anadkat|
|1:30 PM||Skin Adverse Events Induced by Cyotoxic Chemotherapy (Antimicrotubule, ATRA, arsenic trioxide, bleomycin, asparaginase) / Dr. LeBoeuf|
|1:50 PM||Skin Adverse Events Induced by Chemotherapy (Proteasome Inhibitors, Immunotherapies (IFN, ipilimumab, thalidomide, lenalidomide) / Dr. Choi|
|2:10 PM||Skin Adverse Events Induced by EGFR, mTOR, and RAF inhibitors / Dr. Lacouture|
|2:30 PM||Hand Foot Syndrome, Hair, and Nail Changes / Dr. McLellan|
|2:50 PM||Question and Answer Session / All faculty|